Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “Georgia Regents Research Institute, Inc.”

8 pharma patents match "Georgia Regents Research Institute, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 8
Index total 30,257
Page 1 / 1

Quick answer

This filtered view shows 8 pharmaceutical patents matching "Georgia Regents Research Institute, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

8 results for “Georgia Regents Research Institute, Inc.” · 30,257 patents in full index Clear search

  1. US 9267139

    Compositions and methods for treating musculoskeletal diseases and disorders

    Georgia Regents Research Institute, Inc. · Granted Feb 23, 2016 · Expires Feb 18, 2036

    granted
  2. US 9244082

    Detection and treatment of LRP4-associated neurotransmission disorders

    Georgia Regents Research Institute, Inc. · Granted Jan 26, 2016 · Expires Jan 21, 2036

    granted
  3. US 8920854

    Oral care compositions for treating xerostomia

    Georgia Regents Research Institute, Inc. · Granted Dec 30, 2014 · Expires Dec 25, 2034

    granted
  4. US 8877161

    GM1-like peptides and uses thereof

    Georgia Regents Research Institute, Inc. · Granted Nov 4, 2014 · Expires Oct 30, 2034

    granted
  5. US 8816151

    Stat5b transgenic mice and methods of use thereof

    Georgia Regents Research Institute, Inc. · Granted Aug 26, 2014 · Expires Aug 21, 2034

    granted
  6. US 8808715

    Methods and compositions for modulating keratinocyte function

    Georgia Regents Research Institute, Inc. · Granted Aug 19, 2014 · Expires Aug 14, 2034

    granted
  7. US 8754051

    Peptide modulators of the δPKC interaction with the d subunit of F1Fo ATP synthase/ATPase and uses thereof

    Georgia Regents Research Institute, Inc. · Granted Jun 17, 2014 · Expires Jun 12, 2034

    granted
  8. US 8580844

    Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities

    Georgia Regents Research Institute, Inc. · Granted Nov 12, 2013 · Expires Nov 7, 2033

    granted